WIKIMEDIA, HERZOG & DE MEURONRoche has acquired Bina Technologies, a privately-owned biotech company based in California. The biotech’s first product was the Bina Box, a platform for secondary genomic analysis, sequence alignment, and variant calling, but since 2012, it has developed other products and platforms. Bina’s co-founder and CEO Narges Bani Asadi said in a statement that the relationship will be mutually beneficial to both firms. “We found great alignment between our company’s vision and values, and we are very excited about the possibilities of working with Roche's global team and serving the academic and translational and clinical research markets together in the future,” she said.
Dan Zabrowski, head of Roche Sequencing, echoed the sentiment. “The acquisition of Bina is a significant step for Roche to enable the promise of personalized healthcare by delivering the highest quality genomic data possible,” he said. “Informatics and data management are critical to providing a seamless, end-to-end sequencing solution. Bina’s products are designed to improve the efficiency and value of genomic analysis, and the company continues to develop new methodologies and algorithms that link [next-generation sequencing] data to disease-relevant genetic markers.”
The acquisition will amount to an “arm’s length” relationship, Asadi told Bio-IT World. It will allow Bani to further develop and market its Bina Genomic Management System, which Roche will use to process its own genomic data.
“We’re going to have the support of Roche to develop and scale our company much faster than before, and also have access to really deep experience and knowledge in Roche,” she said.
Financial details of the deal were not disclosed. For Roche, the move is yet another in a string of acquisitions. Last week (December 18), Roche paid $489 million for antibody maker Dutalys. And earlier this month, Roche bought prenatal testing company Ariosa Diagnostics.